Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Group was founded by Chairman Xiu Laigui in May 1995. It is a large modern private pharmaceutical enterprise integrating scientific research, production and marketing of patent medicines, chemical medicines, and biopharmaceuticals, pharmaceutical chain operations, and standard cultivation of traditional Chinese medicinal materials. Through secondary development, the group has cultivated more than a dozen major varieties such as Feining, Empty Hydrochloride, Liuwei Dihuang, Neiyaku Kang, Yiqi and Blood Health, etc.; it has integrated the transformation of scientific and technological management, innovative drug research, and new technological achievements into a domestic one. The scientific research system has more than 300 technical experts, more than 700 authorized patents, and won 7 national scientific and technological progress awards. There are nationally certified enterprise technology centers, national engineering laboratories for quality control technology in traditional Chinese medicine, postdoctoral research workstations, and key laboratories for key engineering technology in traditional Chinese medicine standardization. Correcting health is an important support for the big health strategy and an important wing for the revision of the "professional development, two wings flying together" strategy. Starting from 2021, we will focus on health product research and development and health management. Headquarters are located in Changchun, Jilin and Hangzhou, Zhejiang, respectively, including 8 industrial bases, covering an area of more than 1,000 mu. Currently, six industrial bases in Changchun Shuangyang, Jilin Panshi, Baishan Jingyu, Shandong Weifang, Anhui Bozhou and Hangzhou Qiandaohu have been put into production. , sales channels cover multiple channels such as e-commerce, new retail, maternal and infant, pharmacies and supermarket third terminals. Currently, there are about 670 varieties in production and sales, 404 registered trademarks, and 50 patents. Its well-known products such as Spot Cream, Red Bean and Barley Tea, Xiuyisheng Probiotics, Uer Capsules, Svino Oral Liquid, Glycosammonia Chondroitin, and Youzhi DHA are well-known throughout the country, occupying the leading position in the big health sector and are deeply influenced by Good reviews from consumers. The product line covers a variety of dosage forms such as health foods, nourishing foods, fast-selling foods, alternative teas, health wines, mineral water, functional cosmetics, cosmetics, etc.
Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Group was founded by Chairman Xiu Laigui in May 1995. It is a large modern private pharmaceutical enterprise integrating scientific research, production and marketing of patent medicines, chemical medicines, and biopharmaceuticals, pharmaceutical chain operations, and standard cultivation of traditional Chinese medicinal materials. Through secondary development, the group has cultivated more than a dozen major varieties such as Feining, Empty Hydrochloride, Liuwei Dihuang, Neiyaku Kang, Yiqi and Blood Health, etc.; it has integrated the transformation of scientific and technological management, innovative drug research, and new technological achievements into a domestic one. The scientific research system has more than 300 technical experts, more than 700 authorized patents, and won 7 national scientific and technological progress awards. There are nationally certified enterprise technology centers, national engineering laboratories for quality control technology in traditional Chinese medicine, postdoctoral research workstations, and key laboratories for key engineering technology in traditional Chinese medicine standardization. Correcting health is an important support for the big health strategy and an important wing for the revision of the "professional development, two wings flying together" strategy. Starting from 2021, we will focus on health product research and development and health management. Headquarters are located in Changchun, Jilin and Hangzhou, Zhejiang, respectively, including 8 industrial bases, covering an area of more than 1,000 mu. Currently, six industrial bases in Changchun Shuangyang, Jilin Panshi, Baishan Jingyu, Shandong Weifang, Anhui Bozhou and Hangzhou Qiandaohu have been put into production. , sales channels cover multiple channels such as e-commerce, new retail, maternal and infant, pharmacies and supermarket third terminals. Currently, there are about 670 varieties in production and sales, 404 registered trademarks, and 50 patents. Its well-known products such as Spot Cream, Red Bean and Barley Tea, Xiuyisheng Probiotics, Uer Capsules, Svino Oral Liquid, Glycosammonia Chondroitin, and Youzhi DHA are well-known throughout the country, occupying the leading position in the big health sector and are deeply influenced by Good reviews from consumers. The product line covers a variety of dosage forms such as health foods, nourishing foods, fast-selling foods, alternative teas, health wines, mineral water, functional cosmetics, cosmetics, etc.
Huarun Jiangzhong Pharmaceutical Group Co., Ltd.
Jiangzhong Pharmaceutical Co., Ltd. (referred to as "Jiangzhong Pharmaceutical" or "Company") achieved backdoor listing through reorganization of Jiangxi Dongfeng Pharmaceutical Co., Ltd. in 1999. The stock abbreviation is Jiangzhong Pharmaceutical, with the stock code 600750. The company takes the traditional Chinese medicine industry as the core, combines traditional Chinese medicine theory with modern scientific research and technology platforms, and is mainly engaged in the research, development, production and sales of Chinese patent medicines and health foods, including "Jiangzhong", "Chuyuan" and "Yang Jisheng". , "Sanghai" and other trademarks, brand products include Jiangzhong Brand Jianweixiaoshi Tablets, Jiangzhong Brand Compound Grass Coral Lozenges, Lihuo Brand Lactobacillin Tablets, Chuyuan Brand Compound Amino Acid Oral Liquid, Shenling Grass Oral Liquid, Bo Locke, compound fresh bamboo juice liquid, Paishi Granules Sanghai Jinwei, Bazhen Yimu Capsules, etc. After years of development, the company has formed its own core expertise and capabilities in scientific research, production, marketing, etc. In terms of R&D, the R&D strength will be improved by relying on the "National Engineering Research Center for Solid Preparation Manufacturing Technology of Traditional Chinese Medicine", "Jiangzhong Pharmaceutical Base, Key Laboratory of Aerospace Nutrition and Food Engineering" and other engineering research centers and key laboratories; in terms of production, the company was the state in 2019 The Ministry of Ecology and Environment has rated it as the "China Ecological Civilization Award Advanced Collective".
Huarun Jiangzhong Pharmaceutical Group Co., Ltd.
Jiangzhong Pharmaceutical Co., Ltd. (referred to as "Jiangzhong Pharmaceutical" or "Company") achieved backdoor listing through reorganization of Jiangxi Dongfeng Pharmaceutical Co., Ltd. in 1999. The stock abbreviation is Jiangzhong Pharmaceutical, with the stock code 600750. The company takes the traditional Chinese medicine industry as the core, combines traditional Chinese medicine theory with modern scientific research and technology platforms, and is mainly engaged in the research, development, production and sales of Chinese patent medicines and health foods, including "Jiangzhong", "Chuyuan" and "Yang Jisheng". , "Sanghai" and other trademarks, brand products include Jiangzhong Brand Jianweixiaoshi Tablets, Jiangzhong Brand Compound Grass Coral Lozenges, Lihuo Brand Lactobacillin Tablets, Chuyuan Brand Compound Amino Acid Oral Liquid, Shenling Grass Oral Liquid, Bo Locke, compound fresh bamboo juice liquid, Paishi Granules Sanghai Jinwei, Bazhen Yimu Capsules, etc. After years of development, the company has formed its own core expertise and capabilities in scientific research, production, marketing, etc. In terms of R&D, the R&D strength will be improved by relying on the "National Engineering Research Center for Solid Preparation Manufacturing Technology of Traditional Chinese Medicine", "Jiangzhong Pharmaceutical Base, Key Laboratory of Aerospace Nutrition and Food Engineering" and other engineering research centers and key laboratories; in terms of production, the company was the state in 2019 The Ministry of Ecology and Environment has rated it as the "China Ecological Civilization Award Advanced Collective".
Sunflower Pharmaceutical Group Co., Ltd.
Kuihua Pharmaceutical Group Co., Ltd. is based on the mission of "guaranteeing the safety of Chinese children's medication, protecting the healthy growth of Chinese children. Being a good medicine for the people and bringing a healthy and beautiful life to hundreds of millions of families". It has a brand OTC product as the core and covers R&D. , well-known pharmaceutical companies in the entire industrial chain. The group was formerly the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was reorganized into a private enterprise, Heilongjiang Kuihua Pharmaceutical Co., Ltd., and then continued to grow and grew. In 2005, Kuihua Pharmaceutical Group Co., Ltd. was established. The group currently has 32 subsidiaries including 13 pharmaceutical production enterprises, 6 sales companies, 4 pharmaceutical research institutes, 2 medicinal materials planting bases, and 1 pharmaceutical packaging company. It is headquartered in Harbin City. Listed in Shenzhen at the end of 2014, with stock code: 002737. The company is currently the executive vice president unit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the vice president unit of the China Pharmaceutical Enterprise Management Association, the vice president unit of the China Pharmaceutical Business Association, the member unit of the China Traditional Chinese Medicine Association, and the vice president of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association Unit, senior vice president unit of China Over-the-counter Drug Association, etc. Kuihua Pharmaceutical Group is dominated by traditional Chinese medicine, with "chemical drugs, biological drugs" and "healthy and health products" as its two wings, and is in the six major fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, and cardiovascular and cerebrovascular diseases". It has formed a comprehensive layout of product pipelines and has a rich product line, with a total of 21 dosage forms, 257 products in production, and 1,126 drug approval numbers. Among them, nearly 100 children's medicine approval numbers have been held and more than 60 sold drug products. Xiao Kuihua Children's Medicine has unshakable advantages in the same category in the OTC field in terms of "sales scale, product quantity, and scale single products". . The company is an OTC large-scale enterprise with "dual brand umbrellas". "Sunflower" and "Little Sunflower" have built the consumer trust foundation for the company's adult medicine and children's medicine. After more than 20 years of creation, the company has adopted the combination marketing model of "brand model, general medicine model, prescription model, big health model, new retail model" and other combination marketing models to build a unique combination marketing and full model in the industry. The integration model has attracted attention and imitation in the industry.
Sunflower Pharmaceutical Group Co., Ltd.
Kuihua Pharmaceutical Group Co., Ltd. is based on the mission of "guaranteeing the safety of Chinese children's medication, protecting the healthy growth of Chinese children. Being a good medicine for the people and bringing a healthy and beautiful life to hundreds of millions of families". It has a brand OTC product as the core and covers R&D. , well-known pharmaceutical companies in the entire industrial chain. The group was formerly the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was reorganized into a private enterprise, Heilongjiang Kuihua Pharmaceutical Co., Ltd., and then continued to grow and grew. In 2005, Kuihua Pharmaceutical Group Co., Ltd. was established. The group currently has 32 subsidiaries including 13 pharmaceutical production enterprises, 6 sales companies, 4 pharmaceutical research institutes, 2 medicinal materials planting bases, and 1 pharmaceutical packaging company. It is headquartered in Harbin City. Listed in Shenzhen at the end of 2014, with stock code: 002737. The company is currently the executive vice president unit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the vice president unit of the China Pharmaceutical Enterprise Management Association, the vice president unit of the China Pharmaceutical Business Association, the member unit of the China Traditional Chinese Medicine Association, and the vice president of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association Unit, senior vice president unit of China Over-the-counter Drug Association, etc. Kuihua Pharmaceutical Group is dominated by traditional Chinese medicine, with "chemical drugs, biological drugs" and "healthy and health products" as its two wings, and is in the six major fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, and cardiovascular and cerebrovascular diseases". It has formed a comprehensive layout of product pipelines and has a rich product line, with a total of 21 dosage forms, 257 products in production, and 1,126 drug approval numbers. Among them, nearly 100 children's medicine approval numbers have been held and more than 60 sold drug products. Xiao Kuihua Children's Medicine has unshakable advantages in the same category in the OTC field in terms of "sales scale, product quantity, and scale single products". . The company is an OTC large-scale enterprise with "dual brand umbrellas". "Sunflower" and "Little Sunflower" have built the consumer trust foundation for the company's adult medicine and children's medicine. After more than 20 years of creation, the company has adopted the combination marketing model of "brand model, general medicine model, prescription model, big health model, new retail model" and other combination marketing models to build a unique combination marketing and full model in the industry. The integration model has attracted attention and imitation in the industry.
Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.
Xinyi brand, founded in 1916, is currently 100% wholly-owned by Shanghai Pharmaceutical Group Co., Ltd. and is a larger industrial manufacturing enterprise under Shanghai Pharmaceutical Group. As a national pharmaceutical enterprise with a century-old history, Shangyao Xinyi mainly undertakes the social responsibilities of national drug emergency reserves, supporting the state and local governments to promote medical reform, and support social welfare undertakings. At present, Xinyi has become one of the industrial entities with a complete range of product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, a municipal R&D center, and 2 joint ventures, with product approval documents Nearly 1,000, involving 14 major therapeutic areas, covering 20 dosage forms, and there are 2 countries with Class I new drug varieties. There are 405 sales specifications (of which 149 varieties and 270 products have entered the newly issued basic medicine catalogue of the state, accounting for nearly half of the chemical basic medicine catalogue). On the basis of maintaining the competitive advantages of chemical preparations, Xinyi has established the leading position of microecological preparations in the country, as well as four special dosage forms: aerosols, eye drops, soft capsules, and slow-release preparations. In 2011, Peficon was selected as the "national standard strain" of microecological preparations and was awarded the US ATCC standard strain in 2016. Currently, it is applying for registration as an independent intellectual property product in the United States FDA. Since 1999, Xinyi has launched a large-scale public welfare activity "Millions of Citizens See Pudong and Xinyi", which has continued to promote science and health concepts for 19 years, with 520,000 beneficiaries.
Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.
Xinyi brand, founded in 1916, is currently 100% wholly-owned by Shanghai Pharmaceutical Group Co., Ltd. and is a larger industrial manufacturing enterprise under Shanghai Pharmaceutical Group. As a national pharmaceutical enterprise with a century-old history, Shangyao Xinyi mainly undertakes the social responsibilities of national drug emergency reserves, supporting the state and local governments to promote medical reform, and support social welfare undertakings. At present, Xinyi has become one of the industrial entities with a complete range of product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, a municipal R&D center, and 2 joint ventures, with product approval documents Nearly 1,000, involving 14 major therapeutic areas, covering 20 dosage forms, and there are 2 countries with Class I new drug varieties. There are 405 sales specifications (of which 149 varieties and 270 products have entered the newly issued basic medicine catalogue of the state, accounting for nearly half of the chemical basic medicine catalogue). On the basis of maintaining the competitive advantages of chemical preparations, Xinyi has established the leading position of microecological preparations in the country, as well as four special dosage forms: aerosols, eye drops, soft capsules, and slow-release preparations. In 2011, Peficon was selected as the "national standard strain" of microecological preparations and was awarded the US ATCC standard strain in 2016. Currently, it is applying for registration as an independent intellectual property product in the United States FDA. Since 1999, Xinyi has launched a large-scale public welfare activity "Millions of Citizens See Pudong and Xinyi", which has continued to promote science and health concepts for 19 years, with 520,000 beneficiaries.
Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Yabao Pharmaceutical Group Co., Ltd.
In 1992, Ding Gui launched a concentrated herbal essence, which was a small piece of Ding Guier navel patch. The German advanced plant extraction technology is used to extract Chinese herbal essences and use umbilical therapy to treat the baby's belly. Applying the belly button to cure diarrhea, you don’t have to worry about side effects, and save the trouble of feeding medicine. The patch is skin-friendly and breathable, and strives to give your baby a comfortable feeling of delicate skin. Safe and effective, use a suitable method to solve the baby's diarrhea problem. In 2016, Ding Gui launched the Jetsuya Gel, a professional Chinese medicine spleen-strengthening product in China. Choose seven medicines with the same origin as medicine and food to strengthen the spleen and eliminate dampness, treat both symptoms and root causes, and solve the problem of spleen deficiency in your baby. The fruit puree is made in the form of sour and sweet, it does not look like medicine, and it does not taste like medicine; it is safe and effective, and uses a baby's easy-to-accept method to solve the problem of baby not eating. In 2003, Ding Gui launched an oral solution of zinc gluconate for children to supplement important trace elements in the growth and development of the baby. We also studied the zinc supplement standards of the Chinese Nutrition Society, and supplement different amounts at different ages to avoid insufficient amounts and excessive amounts.
Yabao Pharmaceutical Group Co., Ltd.
In 1992, Ding Gui launched a concentrated herbal essence, which was a small piece of Ding Guier navel patch. The German advanced plant extraction technology is used to extract Chinese herbal essences and use umbilical therapy to treat the baby's belly. Applying the belly button to cure diarrhea, you don’t have to worry about side effects, and save the trouble of feeding medicine. The patch is skin-friendly and breathable, and strives to give your baby a comfortable feeling of delicate skin. Safe and effective, use a suitable method to solve the baby's diarrhea problem. In 2016, Ding Gui launched the Jetsuya Gel, a professional Chinese medicine spleen-strengthening product in China. Choose seven medicines with the same origin as medicine and food to strengthen the spleen and eliminate dampness, treat both symptoms and root causes, and solve the problem of spleen deficiency in your baby. The fruit puree is made in the form of sour and sweet, it does not look like medicine, and it does not taste like medicine; it is safe and effective, and uses a baby's easy-to-accept method to solve the problem of baby not eating. In 2003, Ding Gui launched an oral solution of zinc gluconate for children to supplement important trace elements in the growth and development of the baby. We also studied the zinc supplement standards of the Chinese Nutrition Society, and supplement different amounts at different ages to avoid insufficient amounts and excessive amounts.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine. The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies. At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years. Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine. The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies. At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years. Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!
Livzon Pharmaceutical Group Inc.
Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 935 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical research and development, production and sales. It currently has more than 8,000 employees and is an A+H-share listed company. In 2021, the company's operating income was 12.06 billion yuan, net profit was 1.78 billion yuan, and R&D investment was 1.52 billion yuan. Lizhu has made continuous breakthroughs in the fields of raw materials, chemical drugs, traditional Chinese medicines, biological drugs, in vitro diagnostic reagents, etc., and its products are distributed in digestive, cardiovascular, reproductive endocrine, mental/nervous fields. The company continues to focus on the main business of innovative drugs and high-barrier complex preparations, and has launched blockbuster products such as leuprolide and esprazole, achieving large-scale growth in the fields of digestive and reproductive. Lizhu has formed a prescription drug marketing network that radiates across the country and is rapidly promoting the construction of a global sales platform. Through professional academic promotion and high-quality products with accurate efficacy, a good communication channel has been established with hospitals and patients. Lizon's development is inseparable from the continuous joining of outstanding talents and the continuous high-growth R&D investment. The company has built a comprehensive network of scientists and continuously recruited talents around the world. The R&D team has hundreds of doctoral and high-end R&D personnel. In the future, Lizon will continue to focus on the field of life and health, continuously improve the quality of life of patients, continue to shoulder social responsibilities and mission responsibilities, actively participate in public welfare undertakings, and accelerate the company's pace towards globalization.
Livzon Pharmaceutical Group Inc.
Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 935 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical research and development, production and sales. It currently has more than 8,000 employees and is an A+H-share listed company. In 2021, the company's operating income was 12.06 billion yuan, net profit was 1.78 billion yuan, and R&D investment was 1.52 billion yuan. Lizhu has made continuous breakthroughs in the fields of raw materials, chemical drugs, traditional Chinese medicines, biological drugs, in vitro diagnostic reagents, etc., and its products are distributed in digestive, cardiovascular, reproductive endocrine, mental/nervous fields. The company continues to focus on the main business of innovative drugs and high-barrier complex preparations, and has launched blockbuster products such as leuprolide and esprazole, achieving large-scale growth in the fields of digestive and reproductive. Lizhu has formed a prescription drug marketing network that radiates across the country and is rapidly promoting the construction of a global sales platform. Through professional academic promotion and high-quality products with accurate efficacy, a good communication channel has been established with hospitals and patients. Lizon's development is inseparable from the continuous joining of outstanding talents and the continuous high-growth R&D investment. The company has built a comprehensive network of scientists and continuously recruited talents around the world. The R&D team has hundreds of doctoral and high-end R&D personnel. In the future, Lizon will continue to focus on the field of life and health, continuously improve the quality of life of patients, continue to shoulder social responsibilities and mission responsibilities, actively participate in public welfare undertakings, and accelerate the company's pace towards globalization.
Kunming Traditional Chinese Medicine Factory Co., Ltd.
Kun Chinese Medicine started in the 14th year of Hongwu (1381) of Taizu of the Ming Dynasty and officially started construction in the 6th year of Daoguang (1826) of the Qing Dynasty. It has a history of more than 600 years! The company's full name is "Kunming Traditional Chinese Medicine Factory Co., Ltd.", and is a "Chinese time-honored brand" enterprise, a national intangible cultural heritage protection unit, a high-tech enterprise, an Yunnan Enterprise Technology Center, etc. Kun Chinese Medicine is a benchmark enterprise in my country's traditional Chinese medicine industry and represents the development level of advanced traditional Chinese medicine enterprises. Over the past 600 years, the wind and rain have been blowing, spring and autumn fruits have been flourishing. Generations of Kunming Chinese Medicine people have adhered to the spirit of "no reduction and no roughness to cultivate high-quality products, diligent and hardworking, and will be healthy", worked hard, made continuous progress, actively sought, and developed steadily, and achieved remarkable results. Achievements. Kun Chinese Medicine Majinpu production base covers an area of 172 mu, designed with the concept of green, environmentally friendly, energy-saving, simplicity and modernity, and introduced intelligent quality testing equipment and traditional Chinese medicine production equipment, with tablets, pills, granules, capsules, 10 dosage forms including powder, syrup, liniment, wine, paste, and mixture, covering the pretreatment, preparation, outsourcing production line and decoction production line of traditional Chinese medicine production. All of them have passed the national GMP certification and realized the traditional Chinese medicine extraction production line and traditional Chinese medicine plastics. Intelligent control of production lines, packaging connections, logistics and other processes. At present, Kun Chinese Medicine is focusing on the vision of "casting high-quality Chinese medicine and serving healthy life", adheres to the mission of "big medicine is virtuous, and sting is embraced", takes customer service as the basis and value sales as the orientation, and actively implements the "big C model". By reaching a "big consensus" with major chains, entering the TOP chain, carrying out "big drainage", "big training", "big detonation" and "big membership", creating core single-product Shenling Jianpiwei Granules, and opening a new spleen-tonifying new The brand potential of the times. Kunming Chinese medicine products have always been well-known in Southeast Asian countries. Many products of Shugan Granules, Qingfei Huatan Pills, Killing Pills, Gastrodia ejaculation pills, and Gastrodia ejaculation and Wind Replenishment Pills have been successfully registered in Vietnam, Singapore, Indonesia and other countries. Kunming Chinese Medicine has been passed down for a century, with a rich history, unique products and excellent quality. "Quality Kunming Chinese Medicine" is a lofty reputation and brand recognition given by consumers. Kun Chinese Medicine has always developed a large number of advantageous varieties with its unique resources, technology, equipment, talents and network advantages, including Shenling Jianpiwei Granules, Shugan Granules, Oropharyngeal Qingwan, Qingfei Huatan Pills, Banlan Qingre Granules, cold anti-inflammatory tablets, cough pills, Nuanwei Shule granules and other medicines.
Kunming Traditional Chinese Medicine Factory Co., Ltd.
Kun Chinese Medicine started in the 14th year of Hongwu (1381) of Taizu of the Ming Dynasty and officially started construction in the 6th year of Daoguang (1826) of the Qing Dynasty. It has a history of more than 600 years! The company's full name is "Kunming Traditional Chinese Medicine Factory Co., Ltd.", and is a "Chinese time-honored brand" enterprise, a national intangible cultural heritage protection unit, a high-tech enterprise, an Yunnan Enterprise Technology Center, etc. Kun Chinese Medicine is a benchmark enterprise in my country's traditional Chinese medicine industry and represents the development level of advanced traditional Chinese medicine enterprises. Over the past 600 years, the wind and rain have been blowing, spring and autumn fruits have been flourishing. Generations of Kunming Chinese Medicine people have adhered to the spirit of "no reduction and no roughness to cultivate high-quality products, diligent and hardworking, and will be healthy", worked hard, made continuous progress, actively sought, and developed steadily, and achieved remarkable results. Achievements. Kun Chinese Medicine Majinpu production base covers an area of 172 mu, designed with the concept of green, environmentally friendly, energy-saving, simplicity and modernity, and introduced intelligent quality testing equipment and traditional Chinese medicine production equipment, with tablets, pills, granules, capsules, 10 dosage forms including powder, syrup, liniment, wine, paste, and mixture, covering the pretreatment, preparation, outsourcing production line and decoction production line of traditional Chinese medicine production. All of them have passed the national GMP certification and realized the traditional Chinese medicine extraction production line and traditional Chinese medicine plastics. Intelligent control of production lines, packaging connections, logistics and other processes. At present, Kun Chinese Medicine is focusing on the vision of "casting high-quality Chinese medicine and serving healthy life", adheres to the mission of "big medicine is virtuous, and sting is embraced", takes customer service as the basis and value sales as the orientation, and actively implements the "big C model". By reaching a "big consensus" with major chains, entering the TOP chain, carrying out "big drainage", "big training", "big detonation" and "big membership", creating core single-product Shenling Jianpiwei Granules, and opening a new spleen-tonifying new The brand potential of the times. Kunming Chinese medicine products have always been well-known in Southeast Asian countries. Many products of Shugan Granules, Qingfei Huatan Pills, Killing Pills, Gastrodia ejaculation pills, and Gastrodia ejaculation and Wind Replenishment Pills have been successfully registered in Vietnam, Singapore, Indonesia and other countries. Kunming Chinese Medicine has been passed down for a century, with a rich history, unique products and excellent quality. "Quality Kunming Chinese Medicine" is a lofty reputation and brand recognition given by consumers. Kun Chinese Medicine has always developed a large number of advantageous varieties with its unique resources, technology, equipment, talents and network advantages, including Shenling Jianpiwei Granules, Shugan Granules, Oropharyngeal Qingwan, Qingfei Huatan Pills, Banlan Qingre Granules, cold anti-inflammatory tablets, cough pills, Nuanwei Shule granules and other medicines.
Kenvue (pronounced ken·view) is inspired by two powerful concepts: "ken" comes from the Scottish dialect, meaning "knowledge" and "vue" means "vision". With extensive knowledge and insight into consumer needs, Kenvue will bring more meaningful personal health solutions to consumers around the world. "Loyalty to science" is Kenvue 's core proposition for protecting daily health and perpetuity. Kenvue has been seeking innovative solutions that meet people’s daily health needs and is working hard to bring them to consumers. Kenvue 's management team is like Kenvue 's consumers, with a diverse background that brings Kenvue rich experience and a diverse perspective. Kenvue 's purpose is very clear, because Kenvue firmly believes that the meaning of protecting daily health is not only health itself, but also empowering people to live a better life. We hope to convey this power to consumers and let people feel the beauty of this world with energy. Even in the face of difficulties and obstacles, we still insist on choosing the right path. Whether in ordinary daily life or at important and critical moments, Kenvue 's work is crucial to consumers, employees, and society, and will have a profound impact on generations. This huge responsibility means that we must always keep our integrity and quality in mind, and guide every decision and every step of our actions. Only when we practice people-oriented can our business continue to grow. Kenvue 's success stems from the people we serve. Only when Kenvue cares for everyone with all his heart can he create good health solutions. Kenvue works together to create an inclusive environment where everyone can unlock their full potential. Through close cooperation, we can build excellent external competitiveness. Only when our connections become stronger can the company and brand become stronger. From practice to products, Kenvue continues to learn, test, collaborate and optimize, bringing practical solutions to the community, family and everyone quickly. With leading science and technology, Kenvue educates and empowers the public to benefit from our products when they need it. Kenvue has won everyone's trust in the past century and will also be committed to continuing this trust every day in the future. Kenvue listens and addresses unmet needs. From the perspective of patients and consumers, Kenvue continues to make breakthroughs in protecting daily health, and with courage and belief, he promotes the implementation of ideas into reality. Kenvue boldly pursues more innovative ways of working, actively explores the possibility of improving life, creates new product categories, and achieves self-transcendence time and time again. From the first bathing of a newborn baby to pampering the skin or ease pain, Kenvue ’s products are always committed to protecting people’s daily health in a scientific and reliable way.
Kenvue (pronounced ken·view) is inspired by two powerful concepts: "ken" comes from the Scottish dialect, meaning "knowledge" and "vue" means "vision". With extensive knowledge and insight into consumer needs, Kenvue will bring more meaningful personal health solutions to consumers around the world. "Loyalty to science" is Kenvue 's core proposition for protecting daily health and perpetuity. Kenvue has been seeking innovative solutions that meet people’s daily health needs and is working hard to bring them to consumers. Kenvue 's management team is like Kenvue 's consumers, with a diverse background that brings Kenvue rich experience and a diverse perspective. Kenvue 's purpose is very clear, because Kenvue firmly believes that the meaning of protecting daily health is not only health itself, but also empowering people to live a better life. We hope to convey this power to consumers and let people feel the beauty of this world with energy. Even in the face of difficulties and obstacles, we still insist on choosing the right path. Whether in ordinary daily life or at important and critical moments, Kenvue 's work is crucial to consumers, employees, and society, and will have a profound impact on generations. This huge responsibility means that we must always keep our integrity and quality in mind, and guide every decision and every step of our actions. Only when we practice people-oriented can our business continue to grow. Kenvue 's success stems from the people we serve. Only when Kenvue cares for everyone with all his heart can he create good health solutions. Kenvue works together to create an inclusive environment where everyone can unlock their full potential. Through close cooperation, we can build excellent external competitiveness. Only when our connections become stronger can the company and brand become stronger. From practice to products, Kenvue continues to learn, test, collaborate and optimize, bringing practical solutions to the community, family and everyone quickly. With leading science and technology, Kenvue educates and empowers the public to benefit from our products when they need it. Kenvue has won everyone's trust in the past century and will also be committed to continuing this trust every day in the future. Kenvue listens and addresses unmet needs. From the perspective of patients and consumers, Kenvue continues to make breakthroughs in protecting daily health, and with courage and belief, he promotes the implementation of ideas into reality. Kenvue boldly pursues more innovative ways of working, actively explores the possibility of improving life, creates new product categories, and achieves self-transcendence time and time again. From the first bathing of a newborn baby to pampering the skin or ease pain, Kenvue ’s products are always committed to protecting people’s daily health in a scientific and reliable way.
Guangdong Tainkang Pharmaceutical Co., Ltd.
Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang"), stock code 301263. Taienkang was established in 1999. Its main business is agency operation and research and development, production, sales of pharmaceutical products, medical devices, sanitary materials, and providing medical technical services and technology transfer. The main products are Hewei Zhenchan Pills and "Wori" Ting" lecithin complex iodine tablets and "Aitingjiu" dapoxetine hydrochloride tablets. Since its establishment, Taienkang has been agents and operated by Weizhen Chan Chan Wan and Wolitin. As the general agent of China, it is fully responsible for customs declaration, inspection, marketing promotion, distributor selection, sales pricing and other work in the Chinese market, and will promote its operations and promotion respectively. It has become a well-known product in the fields of gastrointestinal medicine and ophthalmic medicine in my country. After more than 20 years of marketing promotion, the company has formed a large-scale sales channel network and team. Through strong in-hospital channel control capabilities and innovative drug promotion models, products can quickly achieve sales revenue after they are launched. In 2015, the company established a R&D subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. Based on the R&D strategy of "innovative drug research and development as the top, improved new drugs and biopharmaceuticals as the tower body, and generic drugs as the foundation", a functional auxiliary materials and nano-dose technology platform, a biomacromolecular drug technology platform and generic drugs have been built. Development and consistency evaluation technology platform. The company's independently developed "Aitingjiu" dapoxetine hydrochloride tablets is the "first imitation" in China. Tadalafil has obtained the drug registration approval document and obtained the first clinical trial of docetaxel polymer micelles for injection in China in 2018. Approval and signed a project transfer agreement with Fosun Pharma. In addition, the company also reserves a large number of independent drug research and development projects, among which Praxol Hydrochloride sustained release tablets, ornizolazone injection, and Agatroban injection have submitted drug registration approval applications, and ranibizumab injection is about to apply for clinical application. test. In the next three years, the company expects that the products under development will be approved for listing every year, which will continue to drive the company's product pipeline enrichment and rapid growth in profitability.
Guangdong Tainkang Pharmaceutical Co., Ltd.
Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang"), stock code 301263. Taienkang was established in 1999. Its main business is agency operation and research and development, production, sales of pharmaceutical products, medical devices, sanitary materials, and providing medical technical services and technology transfer. The main products are Hewei Zhenchan Pills and "Wori" Ting" lecithin complex iodine tablets and "Aitingjiu" dapoxetine hydrochloride tablets. Since its establishment, Taienkang has been agents and operated by Weizhen Chan Chan Wan and Wolitin. As the general agent of China, it is fully responsible for customs declaration, inspection, marketing promotion, distributor selection, sales pricing and other work in the Chinese market, and will promote its operations and promotion respectively. It has become a well-known product in the fields of gastrointestinal medicine and ophthalmic medicine in my country. After more than 20 years of marketing promotion, the company has formed a large-scale sales channel network and team. Through strong in-hospital channel control capabilities and innovative drug promotion models, products can quickly achieve sales revenue after they are launched. In 2015, the company established a R&D subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. Based on the R&D strategy of "innovative drug research and development as the top, improved new drugs and biopharmaceuticals as the tower body, and generic drugs as the foundation", a functional auxiliary materials and nano-dose technology platform, a biomacromolecular drug technology platform and generic drugs have been built. Development and consistency evaluation technology platform. The company's independently developed "Aitingjiu" dapoxetine hydrochloride tablets is the "first imitation" in China. Tadalafil has obtained the drug registration approval document and obtained the first clinical trial of docetaxel polymer micelles for injection in China in 2018. Approval and signed a project transfer agreement with Fosun Pharma. In addition, the company also reserves a large number of independent drug research and development projects, among which Praxol Hydrochloride sustained release tablets, ornizolazone injection, and Agatroban injection have submitted drug registration approval applications, and ranibizumab injection is about to apply for clinical application. test. In the next three years, the company expects that the products under development will be approved for listing every year, which will continue to drive the company's product pipeline enrichment and rapid growth in profitability.
Daxi® Aluminum Magnesium Carbonate Chewable Tablets are from a well-known gastric drug brand with century-old pharmaceutical experience in Germany. They have been in China for more than 20 years. Focus on protecting your stomach health, whether it is work, family, travel, food, or gatherings... At every critical moment, Daxi is accompanied. I control the wonderful life "stomach"!
Bayer HealthCare AG
Daxi® Aluminum Magnesium Carbonate Chewable Tablets are from a well-known gastric drug brand with century-old pharmaceutical experience in Germany. They have been in China for more than 20 years. Focus on protecting your stomach health, whether it is work, family, travel, food, or gatherings... At every critical moment, Daxi is accompanied. I control the wonderful life "stomach"!
Sichuan Taihuatang Pharmaceutical Co., Ltd.
Sichuan Taihuatang Pharmaceutical Co., Ltd. was founded in 1988 and is a modern pharmaceutical enterprise under the Sichuan Natural Resources Investment Group. Over the years, Taihuatang has always adhered to the spirit of "two bombs and one satellite", and has taken "leading modern science and technology and promoting traditional Chinese medicine culture" as its corporate mission, striving for excellence and developing distinctively. The company now covers an area of nearly 200 mu and has more than 1,000 employees. It has 8 national GMP production lines including capsules, tablets, oral liquids, and 82 products. The products involve multiple treatment areas such as nourishing and replenishing the body, digestive system, cardiovascular and cerebrovascular, tumor auxiliary drugs, gynecological drugs, antibiotics, antipyretic and analgesic drugs. The company is currently a high-tech enterprise in Sichuan Province and an independent intellectual property advantage enterprise in Sichuan Province.
Sichuan Taihuatang Pharmaceutical Co., Ltd.
Sichuan Taihuatang Pharmaceutical Co., Ltd. was founded in 1988 and is a modern pharmaceutical enterprise under the Sichuan Natural Resources Investment Group. Over the years, Taihuatang has always adhered to the spirit of "two bombs and one satellite", and has taken "leading modern science and technology and promoting traditional Chinese medicine culture" as its corporate mission, striving for excellence and developing distinctively. The company now covers an area of nearly 200 mu and has more than 1,000 employees. It has 8 national GMP production lines including capsules, tablets, oral liquids, and 82 products. The products involve multiple treatment areas such as nourishing and replenishing the body, digestive system, cardiovascular and cerebrovascular, tumor auxiliary drugs, gynecological drugs, antibiotics, antipyretic and analgesic drugs. The company is currently a high-tech enterprise in Sichuan Province and an independent intellectual property advantage enterprise in Sichuan Province.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Hutchison Huangpu Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Huangpu") was jointly established in May 2005 by the Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group and Hutchison Huangpu (China) Company, a subsidiary of Mr. Li Ka-shing. The joint venture was formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory. It was established in May 1988. It was derived from the farm operation area established in 1956 and was transformed into a tonic factory that combines agriculture and industry, and then transformed into Guangzhou Baiyun, which operates the pharmaceutical and health industry. Shan Chinese Medicine Factory. The company stands at the forefront of the times and the height of the industry, takes the cross policy of "education, love, technology, innovation, responsibility" as a guide, and takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine" as its mission, and takes economic benefits. As the center, we focus on management internally, expand the market externally, and implement the three major strategies of "talent, brand, and technology", forming five core competitive advantages: scientific and technological innovation, responsible marketing, cultural heritage, talent engineering, and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, collection, output value and profit maintained a growth of more than 30%. The company actively builds a pioneer modern Chinese medicine enterprise and enters into advantageous enterprises in the big health industry.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Hutchison Huangpu Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Huangpu") was jointly established in May 2005 by the Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group and Hutchison Huangpu (China) Company, a subsidiary of Mr. Li Ka-shing. The joint venture was formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory. It was established in May 1988. It was derived from the farm operation area established in 1956 and was transformed into a tonic factory that combines agriculture and industry, and then transformed into Guangzhou Baiyun, which operates the pharmaceutical and health industry. Shan Chinese Medicine Factory. The company stands at the forefront of the times and the height of the industry, takes the cross policy of "education, love, technology, innovation, responsibility" as a guide, and takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine" as its mission, and takes economic benefits. As the center, we focus on management internally, expand the market externally, and implement the three major strategies of "talent, brand, and technology", forming five core competitive advantages: scientific and technological innovation, responsible marketing, cultural heritage, talent engineering, and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, collection, output value and profit maintained a growth of more than 30%. The company actively builds a pioneer modern Chinese medicine enterprise and enters into advantageous enterprises in the big health industry.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Handan Pharmaceutical Co., Ltd.
Handan Pharmaceutical Co., Ltd., established in 1998, is currently a national high-tech enterprise, a national GMP certified enterprise, a key leading enterprise in agricultural industrialization in Hebei Province, a integrity enterprise in Hebei Province, a Chinese medicine international cooperation base, and a contract abiding by the State Administration for Industry and Commerce. Credit-oriented enterprises, "specialized, specialized, and innovative" demonstration enterprises, etc. Handan Pharmaceutical Company takes promoting ethnic medicine as its mission, takes science and technology as its guide, and product quality as its life. It inherits traditional preparation technology, brings together modern technology, integrates modern preparation technology to create Huashan brand "Morodan" and "Sanhuang Tablets" , "Children Fengreqing", "Danqi Granules", "Liuzhai Pills", etc., reserves 116 products with national medicines, and has tablets, pills, mixtures, capsules, granules, and syrups. and other modern preparation production lines of six major dosage forms. The products are sold well across the country and are exported to Europe, America, Southeast Asia and other countries and regions. The "Huashan Brand" trademark has obtained the exclusive protection rights of trademarks of 77 member states to the Madrid Protocol. Handan Pharmaceutical Co., Ltd. continues to be committed to the research and development, production and value transfer of high-quality Chinese patent medicines.
Handan Pharmaceutical Co., Ltd.
Handan Pharmaceutical Co., Ltd., established in 1998, is currently a national high-tech enterprise, a national GMP certified enterprise, a key leading enterprise in agricultural industrialization in Hebei Province, a integrity enterprise in Hebei Province, a Chinese medicine international cooperation base, and a contract abiding by the State Administration for Industry and Commerce. Credit-oriented enterprises, "specialized, specialized, and innovative" demonstration enterprises, etc. Handan Pharmaceutical Company takes promoting ethnic medicine as its mission, takes science and technology as its guide, and product quality as its life. It inherits traditional preparation technology, brings together modern technology, integrates modern preparation technology to create Huashan brand "Morodan" and "Sanhuang Tablets" , "Children Fengreqing", "Danqi Granules", "Liuzhai Pills", etc., reserves 116 products with national medicines, and has tablets, pills, mixtures, capsules, granules, and syrups. and other modern preparation production lines of six major dosage forms. The products are sold well across the country and are exported to Europe, America, Southeast Asia and other countries and regions. The "Huashan Brand" trademark has obtained the exclusive protection rights of trademarks of 77 member states to the Madrid Protocol. Handan Pharmaceutical Co., Ltd. continues to be committed to the research and development, production and value transfer of high-quality Chinese patent medicines.
Metoclopramide is a medication that increases stomach contractions, treating nausea and acid reflux.
Various Generics
Metoclopramide is a medication that increases stomach contractions, treating nausea and acid reflux.
Tums is a popular antacid brand that provides quick relief from heartburn and indigestion.
GlaxoSmithKline
Tums is a popular antacid brand that provides quick relief from heartburn and indigestion.
